Inhibition of insulin‐like growth factor 2 mRNA ‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics
FASEB BioAdvances · 2022-12 · 4 (12) · 816-829
DOI: 10.1096/fba.2021-00069 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 05.10.2022. Verfasst von Nicole Betson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology Jackson State University Jackson Mississippi USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS, National Institute on Minority Health and Health Disparities.
Abstract (Originalsprache)
Although colorectal cancer (CRC) treatment has seen a remarkable improvement in the recent years, many patients will develop metastasis due to the resistance of cancer cells to chemotherapeutics. Targeting mechanisms driving the resistance of CRC cells to treatment would significantly reduce cases of metastasis and death. Induction of insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1), a direct target of the Wnt/β‐catenin signaling pathway, might promote resistance of CRC cells to treatment via activation of anti‐apoptotic pathways and induction of the multidrug resistance (MDR1) membrane transporter that pumps drugs out of the cells. We hypothesized that inhibition of IGF2BP1 will sensitize CRC cells to chemotherapeutics. We used CRC cell lines with different status of activation of Wnt signaling to show that inhibition of IGF2BP1 potentiates the anti‐growth and anti‐proliferative effects of chemotherapeutics on CRC cells with activated Wnt/β‐catenin signaling pathway. We observed that the inhibition of IGF2BP1 significantly increases apoptosis in the same cells. A remarkable reduction in the migratory capability of those cells was noted as well. We found that inhibition of IGF2BP1 is sufficient to decrease the resistance of chemotherapy‐resistant cancer cells with activated Wnt/β‐catenin signaling pathway. These findings portray IGF2BP1 as a good candidate for CRC therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology Jackson State University Jackson Mississippi USA.
- Research Centers in Minority Institutions (RCMI), Center for Health Disparity Research (RCMI-CHDR) Jackson State University Jackson Mississippi USA.
- Division of Pediatric Hematology/Oncology Pennsylvania State University, Hershey Medical Center Hershey Pennsylvania USA.
ORCID-Profile: Paul B Tchounwou, Felicite K Noubissi
Förderung
- NCI NIH HHS
- NIMHD NIH HHS
- National Institute on Minority Health and Health Disparities
Zitieren
APA
Betson, N., Hajahmed, M., Gebretsadek, T., Ndebele, K., Ahmad, H. A., Tchounwou, P. B., Spiegelman, V. S., & Noubissi, F. K. (2022). Inhibition of insulin‐like growth factor 2 mRNA ‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics. FASEB BioAdvances, 4(12), 816-829. https://doi.org/10.1096/fba.2021-00069
Vancouver
Betson N, Hajahmed M, Gebretsadek T, Ndebele K, Ahmad HA, Tchounwou PB, et al. Inhibition of insulin‐like growth factor 2 mRNA ‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics. FASEB BioAdvances. 2022;4(12):816-829. doi:10.1096/fba.2021-00069
BibTeX
@article{Betson2022,
author = {Betson, Nicole and Hajahmed, Mohammed and Gebretsadek, Tsige and Ndebele, Kenneth and Ahmad, H Anwar and Tchounwou, Paul B and Spiegelman, Vladimir S and Noubissi, Felicite K},
title = {Inhibition of insulin‐like growth factor 2 mRNA ‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics},
journal = {FASEB BioAdvances},
year = {2022},
volume = {4},
number = {12},
pages = {816--829},
doi = {10.1096/fba.2021-00069}
}
EUVIMED